StockData
ANI Pharmaceuticals Inc logo

ANI Pharmaceuticals Inc (ANIP) stock

ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$69.99−0.90 (-1.27%)

Close on Nov 17, 2026Market cap $1.61BP/E 14.9Yield –

ANI Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

ANI Pharmaceuticals's total assets was $1.49B at Jun 30, 2026. For fiscal 2025 it was $1.44B, up 12.1% from the year before. Over ten years it grew 17.6% a year on average. The highest annual figure on record is $1.44B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.44B+12.1%
FY2024Dec 31, 2024$1.28B+42.0%
FY2023Dec 31, 2023$904.42M+19.0%
FY2022Dec 31, 2022$760.09M-1.5%
FY2021Dec 31, 2021$771.60M+67.3%
FY2020Dec 31, 2020$461.19M+1.0%
FY2019Dec 31, 2019$456.79M+6.1%
FY2018Dec 31, 2018$430.60M+4.5%
FY2017Dec 31, 2017$412.14M+27.7%
FY2016Dec 31, 2016$322.86M+13.2%
FY2015Dec 31, 2015$285.27M+9.9%
FY2014Dec 31, 2014$259.56M+483.3%
FY2013Dec 31, 2013$44.50M+223.7%
FY2012Dec 31, 2012$13.75M-78.0%
FY2011Dec 31, 2011$62.38M+39.3%
FY2010Dec 31, 2010$44.77M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.49B+11.3%
Q1 FY2026Mar 31, 2026$1.42B+10.0%
Q4 FY2025Dec 31, 2025$1.44B+12.1%
Q3 FY2025Sep 30, 2025$1.41B+9.4%
Q2 FY2025Jun 30, 2025$1.34B+45.9%
Q1 FY2025Mar 31, 2025$1.29B+41.3%
Q4 FY2024Dec 31, 2024$1.28B+42.0%
Q3 FY2024Sep 30, 2024$1.29B+44.7%
Q2 FY2024Jun 30, 2024$920.75M+7.1%
Q1 FY2024Mar 31, 2024$914.52M+19.5%
Q4 FY2023Dec 31, 2023$904.42M+19.0%
Q3 FY2023Sep 30, 2023$889.91M+20.4%
Q2 FY2023Jun 30, 2023$859.34M+14.4%
Q1 FY2023Mar 31, 2023$765.22M+2.7%
Q4 FY2022Dec 31, 2022$760.09M-1.5%
Q3 FY2022Sep 30, 2022$739.11M+57.1%
Q2 FY2022Jun 30, 2022$751.33M+56.5%
Q1 FY2022Mar 31, 2022$744.85M+60.6%
Q4 FY2021Dec 31, 2021$771.60M+67.3%
Q3 FY2021Sep 30, 2021$470.45M+1.7%
Q2 FY2021Jun 30, 2021$480.16M+3.2%
Q1 FY2021Mar 31, 2021$463.84M-3.8%
Q4 FY2020Dec 31, 2020$461.19M+1.0%
Q3 FY2020Sep 30, 2020$462.58M+1.3%
Q2 FY2020Jun 30, 2020$465.39M+4.1%
Q1 FY2020Mar 31, 2020$482.23M+11.0%
Q4 FY2019Dec 31, 2019$456.79M+6.1%
Q3 FY2019Sep 30, 2019$456.78M+3.9%
Q2 FY2019Jun 30, 2019$446.91M+5.4%
Q1 FY2019Mar 31, 2019$434.39M+3.9%
Q4 FY2018Dec 31, 2018$430.60M+4.5%
Q3 FY2018Sep 30, 2018$439.44M+18.6%
Q2 FY2018Jun 30, 2018$424.18M+18.1%
Q1 FY2018Mar 31, 2018$418.02M+17.0%
Q4 FY2017Dec 31, 2017$412.14M+27.7%
Q3 FY2017Sep 30, 2017$370.47M+16.0%
Q2 FY2017Jun 30, 2017$359.22M–
Q1 FY2017Mar 31, 2017$357.14M–
Q4 FY2016Dec 31, 2016$322.86M–
Q3 FY2016Sep 30, 2016$319.38M–

More ANI Pharmaceuticals figures

See a number that looks wrong?